KEGG   DRUG: Aflibercept
Entry
D09574                      Drug                                   
Name
Aflibercept (USAN/INN);
Aflibercept (genetical recombination) (JAN);
Aflibercept (genetical recombination) [Aflibercept biosimilar 1] (JAN);
Ziv-aflibercept;
Eylea (TN);
Zaltrap (TN)
Product
EYLEA (Regeneron Pharmaceuticals), EYLEA HD (Regeneron Pharmaceuticals), ZALTRAP (sanofi-aventis U.S. LLC)
Formula
C4318H6788N1164O1304S32
Exact mass
96837.1694
Mol weight
96897.1957
Sequence
SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS
RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL
VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ
GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH
YTQKSLSLSP G
(Disulfide bridge: 30-79, 124-185, 246-306, 352-410, 211-211', 214-214')
  Type
Peptide
Remark
Therapeutic category: 1319
ATC code: L01XX44 S01LA05
Product: D09574<JP/US>
Efficacy
Angiogenesis inhibitor
  Disease
Age-related macular degeneration [DS:H00821]
Macular edema [DS:H01651]
Diabetic macular edema [DS:H01651]
Diabetic retinopathy [DS:H01457]
Colorectal cancer [DS:H00020]
Comment
fusion protein
VEGF-Trap
Inhibitor of aberrant angiogenesis-vascular leak and inflammation, angiogenesis inhibitor for treatment of cancer
Target
VEGFA [HSA:7422] [KO:K05448]
VEGFB [HSA:7423] [KO:K16858]
PGF [HSA:5228] [KO:K16859]
  Pathway
hsa04370  VEGF signaling pathway
hsa05200  Pathways in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XX Other antineoplastic agents
     L01XX44 Aflibercept
      D09574  Aflibercept (USAN/INN) <JP/US>
 S SENSORY ORGANS
  S01 OPHTHALMOLOGICALS
   S01L OCULAR VASCULAR DISORDER AGENTS
    S01LA Antineovascularisation agents
     S01LA05 Aflibercept
      D09574  Aflibercept (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antineoplastics, Other
   Ziv-aflibercept
    D09574  Aflibercept (USAN/INN)
 Ophthalmic Agents
  Ophthalmic Agents, Other
   Aflibercept
    D09574  Aflibercept (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  13  Agents affecting sensory organs
   131  Ophthalmic agents
    1319  Others
     D09574  Aflibercept (USAN/INN); Aflibercept (genetical recombination) (JAN); Aflibercept (genetical recombination) [Aflibercept biosimilar 1] (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    PGF
     D09574  Aflibercept (USAN/INN) <JP/US>
    VEGFA
     D09574  Aflibercept (USAN/INN) <JP/US>
    VEGFB
     D09574  Aflibercept (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09574
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09574
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09574
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09574
Other DBs
CAS: 862111-32-8
PubChem: 124490314
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system